


## METHODS

Figure 1. Study Design



\*All doses were given twice weekly for 2 weeks

## METHODS (CONT'D)

- Subjects in Study 204 received a total of 4 doses of CINRYZE with rHuPH20 (on Days 1, 4, 8, 11) during the study period
- Safety was assessed by monitoring adverse events (AEs), changes in vital signs, and laboratory testing
- Presence of C1 INH antibodies was assessed on Day 18 and 30 days after the last dose of study drug
- Pharmacokinetic parameters:
  - Plasma C1 INH functional activity was assessed by chromogenic assay and plasma C1 INH antigenic concentration and C4 complement levels were assessed by ELISA
  - Noncompartmental model analysis (WinNonlin 5.3) was performed on the concentration-versus-time data
  - Parameters of interest: area under the curve at steady state ( $AUC_{tau}$ ; exposure at steady state considered between 0-96 hr),  $C_{max}$ , average concentration at steady state ( $C_{avg}$ ), and relative bioavailability (F)